Episode 57– Jaideep Dudani - CEO Ouro Medicines

Welcome to another episode of The Bio Hub. We were thrilled to welcome Jaideep Dudani, Founding CEO of Ouro Medicines and Portfolio Principal at Monograph Capital. Jaideep holds a PhD from MIT and a BS in Bioengineering from UCLA. Jaideep began his career at Vida Ventures and played key R&D, strategy, and business development roles at Relay Therapeutics. Jaideep later helped launch Human Immunology Biosciences (HI Bio), leading portfolio development and strategic initiatives prior to its acquisition by Biogen.In early 2025, he co founded Ouro Medicines—backed by Monograph, GSK, NEA, TPG, Norwest, and others to pull of an incredible $120M Series A, to pioneer ‘immune reset’ T cell engager therapies targeting B cell mediated autoimmune and inflammatory diseases. We’ll explore Jaideep's journey from bioengineering research to biotech entrepreneurship, as well as the promising data from Ouro Medicines as well as Jaideep’s experience with building biotechs out from the ground up.